Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $5.5 million, compared to $49.8 million for the full year, with a significant portion coming from licensing revenue of $4.3 million from Novo Nordisk [23] - Research and development expenses decreased to $11.3 million in Q4 2025 from $26.7 million in Q4 2024, and full year expenses dropped to $61.1 million from $84.5 million [24] - Selling, general and administrative expenses for Q4 2025 were $8.8 million, down from $32.3 million in Q4 2024, with full year expenses decreasing to $37.3 million from $143.1 million [24][25] - Net loss for Q4 2025 was $15.5 million or $0.04 per share, compared to a net loss of $33.8 million or $0.09 per share in Q4 2024 [25] - As of December 31, 2025, cash investments and restricted cash totaled $125.2 million, down from $238 million at the end of 2024 [26] Business Line Data and Key Metrics Changes - The company is advancing three late-stage programs: sotagliflozin for cardiometabolic disease, pilavapadin for chronic pain, and LX9851 for obesity [4][5] - Sotagliflozin is in late-stage development for hypertrophic cardiomyopathy (HCM) and type 1 diabetes, with an NDA resubmission expected in 2026 [6][12] - Pilavapadin is phase 3-ready for diabetic peripheral neuropathic pain (DPNP), with a successful end of Phase II meeting with the FDA [20][21] Market Data and Key Metrics Changes - The company is focusing on the cardiometabolic disease and chronic pain markets, with significant unmet needs in both areas [9][11] - There are approximately 1 million patients with type 1 diabetes in the U.S., highlighting the market potential for Zynquista if approved [17][18] Company Strategy and Development Direction - The company aims to maintain operational discipline and improve its financial position to support core programs [7] - A partnership strategy is in place to support existing collaborations and explore new partnerships, particularly for pilavapadin [6][19] - The company is focused on driving multiple pivotal milestones in 2026 across its core programs [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's progress and the potential for significant value creation from upcoming catalysts [30] - The company is optimistic about completing enrollment in the SONATA-HCM trial and anticipates data readouts in 2027 [66][67] Other Important Information - The company has reduced total debt by approximately $46.3 million in 2025, primarily using proceeds from the Novo Nordisk upfront payment [28] - Operating expenses were reduced by $39 million in Q4 2025 compared to Q4 2024, reflecting strategic repositioning [28] Q&A Session Summary Question: What is the status of the Steno-1 study data for DKA safety? - Management expects a 6-month review for the NDA resubmission and is tracking data that gives confidence in submission and approval timelines [33][34] Question: How have the Phase 2 results impacted partnership discussions for pilavapadin? - Discussions with potential partners are ongoing, and the end of Phase 2 meeting has provided confidence around moving into Phase 3 [39][40] Question: What are Novo Nordisk's plans for LX9851? - The company believes Novo is exploring various options for LX9851, including its use in combination therapies for obesity management [41][42] Question: Is there flexibility to start the pilavapadin study without a partner? - The company is focused on cardiometabolic opportunities and is preparing for the Phase 3 program while engaging in partnership discussions [48][49] Question: What changes will be made to the Phase 3 design of pilavapadin? - The company plans to expand enrollment criteria and improve patient training on pain score assessments to mitigate placebo response [70][73]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $5.5 million, and for the full year 2025, revenues were $49.8 million, compared to $25 million in upfront payment from Viatris in 2024 [24][26] - Research and development expenses decreased to $11.3 million in Q4 2025 from $26.7 million in 2024, and full year R&D expenses decreased to $61.1 million from $84.5 million [25] - Selling, general and administrative expenses for Q4 2025 decreased to $8.8 million from $32.3 million in 2024, and full year SG&A expenses decreased to $37.3 million from $143.1 million [25] - Net loss for Q4 2025 was $15.5 million or $0.04 per share, compared to a net loss of $33.8 million or $0.09 per share in Q4 2024 [26] - As of December 31, 2025, cash investments and restricted cash totaled $125.2 million, down from $238 million at the end of 2024 [27] Business Line Data and Key Metrics Changes - The company is advancing three late-stage programs: sotagliflozin for cardiometabolic disease, pilavapadin for chronic pain, and LX9851 for obesity [4][5] - Sotagliflozin is in late-stage development for hypertrophic cardiomyopathy (HCM) and type 1 diabetes, with an NDA resubmission expected in 2026 [6][18] - Pilavapadin is phase 3-ready for diabetic peripheral neuropathic pain (DPNP), with a successful end of Phase 2 meeting with the FDA [20][22] Market Data and Key Metrics Changes - The company is focusing on the cardiometabolic disease and chronic pain markets, with significant unmet needs in both areas [10][12] - There are approximately 1 million patients with type 1 diabetes in the U.S., with no new therapies approved for over a century [18] - The SONATA-HCM Phase 3 study is the only registrational trial currently enrolling patients with both obstructive and non-obstructive HCM [14][15] Company Strategy and Development Direction - The company aims to maintain operational discipline and improve its financial position to support core programs [8] - A partnership strategy is in place to support existing licensees and explore new partnerships, particularly for pilavapadin [7] - The company is focused on driving multiple pivotal milestones in 2026 across its core programs [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming milestones and the potential for substantial value creation from its pipeline [30][31] - The company is excited about the progress made in 2025 and the potential opportunities in 2026, emphasizing the importance of addressing unmet medical needs [30][31] Other Important Information - The company has strengthened its cash position with over $100 million from a recent capital raise and a milestone payment from Novo Nordisk [8][27] - The company plans to reduce total operating expenses to between $100 million and $110 million in 2026 [29] Q&A Session Summary Question: What is the status of the Steno-1 study data for DKA safety? - Management expects a 6-month review for the NDA resubmission and is confident in the data supporting submission and approval timelines [33][36] Question: How have the Phase 2 results accelerated partnering discussions for pilavapadin? - Discussions with partners have become more specific following the end of Phase 2 meeting, but no acceleration in discussions has been noted [38][39] Question: What are Novo Nordisk's plans for LX9851? - The company believes Novo is exploring various options for LX9851, including its use in combination therapies for obesity management [40][41] Question: Is there flexibility to start the pilavapadin study without a partner? - The company is focused on cardiometabolic opportunities and is preparing for the Phase 3 program while engaging in partnership discussions [46][48] Question: How confident is the company in achieving the enrollment target for SONATA-HCM? - Management is confident in meeting the mid-year enrollment target, with strong enrollment trends observed across all regions [60][64] Question: What changes will be made to the Phase 3 design of the pilavapadin program? - The company plans to expand enrollment criteria and enhance patient training on pain score assessments to improve consistency [67][70]

Fourth Quarter and Full Year 2025 Earnings M a r c h 5 , 2026 Forward-Looking Statements 2 • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of sotagliflozin, pi ...

Core Insights - Lexicon Pharmaceuticals has made significant progress in its pipeline and financial position, with key milestones achieved in 2025 and a strong start to 2026 [2][3] Financial Performance - Total revenues for Q4 2025 were $5.5 million, with annual revenues of $49.8 million, including $4.3 million from licensing revenue and $1.1 million from net sales of INPEFA [12] - The company reported a net loss of $15.5 million for Q4 2025, a reduction from a net loss of $33.8 million in Q4 2024, and a full-year net loss of $50.3 million compared to $200.4 million in 2024 [16] - Research and development expenses decreased to $11.3 million in Q4 2025 from $26.7 million in 2024, while full-year R&D expenses were $61.1 million, down from $84.5 million [14] - Selling, general and administrative expenses also saw a significant decrease, totaling $8.8 million in Q4 2025 compared to $32.3 million in Q4 2024, and $37.3 million for the full year versus $143.1 million in 2024 [15] Pipeline Developments - Sotagliflozin, an oral SGLT1 and SGLT2 inhibitor, has been studied in approximately 20,000 patients and is commercially available in the U.S. for heart failure as INPEFA [4] - The SONATA-HCM study, a pivotal Phase 3 trial for hypertrophic cardiomyopathy, has surpassed 50% enrollment with a target of 500 patients and is expected to complete enrollment by mid-2026 [8] - Lexicon is on track for a potential NDA resubmission for ZYNQUISTA in Type 1 Diabetes in 2026, contingent on meeting FDA requirements [8] Strategic Partnerships and Funding - The company strengthened its financial position with over $100 million in additional cash from a capital raise and a milestone payment from Novo Nordisk [3][19] - Lexicon has entered into a licensing agreement with Viatris for the commercialization of sotagliflozin outside the U.S. and Europe, with regulatory submissions planned for several markets in 2026 [7][9] Regulatory and Development Readiness - A successful End-of-Phase 2 meeting with the FDA for pilavapadin confirms its readiness for Phase 3 development, which will include placebo-controlled studies [17] - The company is actively engaged in partnership discussions to maximize the global potential of its investigational therapies [17]

Core Insights - Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is recognized as a rapidly growing penny stock, with analysts highlighting its potential for investment [1] - Citi analyst Yigal Nochomovitz raised the price target for Lexicon from $1.90 to $2.10, maintaining a Buy rating due to an updated financial model reflecting milestones in the LX9851 partnership with Novo Nordisk [1][3] Financial Performance - In Q3 2025, Lexicon reported revenue of $14.2 million, primarily driven by $13.2 million in licensing revenue from its partnership with Novo Nordisk [2] - The company's net loss decreased to $12.8 million, or $0.04 per share, compared to a net loss of $64.8 million in the previous year [2] Research and Development Milestones - Lexicon achieved significant R&D milestones, including the completion of all IND-enabling studies for its obesity candidate LX9851, which have been submitted to Novo Nordisk for clinical development [3] - The company is advancing its heart failure medication, INPEFA, into international markets through licensee Viatris and has submitted additional data to the FDA to support the benefit-risk profile for Zynquista in type 1 diabetes [3]

Market Outlook - Lale Akoner from eToro suggests that 2026 will see a rotation into small-cap stocks, advising diversification away from growth technology stocks towards consumer-sensitive stocks and banks [1][2] - Recent data from BofA indicates that customers have been selling equities and there are outflows from ETFs, but this is seen as a rotation within risk assets rather than a move away from them [1] - The anticipated rate-cutting cycle, end of quantitative tightening, and financial deregulation are expected to support risk assets [2] Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) - Lexicon Pharmaceuticals reported Q3 2025 revenue of $14.2 million, primarily from a $13.2 million licensing agreement with Novo Nordisk, with a narrowed net loss of $12.8 million or $0.04 per share compared to a loss of $64.8 million the previous year [9] - The company achieved key R&D milestones, including the completion of IND-enabling studies for its obesity candidate LX9851 and advancing its heart failure medication INPEFA into international markets [10] - Citi analyst Yigal Nochomovitz raised Lexicon's price target to $2.10 from $1.90, maintaining a Buy rating based on updated financial models [8] Strive Inc. (NASDAQ:ASST) - Strive Inc. reported an average upside potential of 90.02% and has been recognized as a fast-growing penny stock [11] - The company announced the acquisition of Semler Scientific, positioning itself as the 11th largest public corporate holder of Bitcoin with approximately 12,797.9 BTC [12] - In Q3 2025, Strive raised $762.6 million through PIPE financing and warrant exercises, establishing itself as a publicly traded Bitcoin treasury asset management firm [13]

Company Overview - Lexicon Pharmaceuticals was founded 30 years ago with the ambitious goal of creating knockout mouse lines for 5,000 genes to study their impacts [3] - The company has conducted over 80 clinical trials, leading to the approval of 2 medicines in the United States [4] Product Development - Lexicon has successfully commercialized INPEFA and developed a non-opioid treatment for neuropathic pain, as well as a new non-incretin mechanism for obesity [4]

Lexicon Pharmaceuticals FY Conference Summary Company Overview - **Company**: Lexicon Pharmaceuticals (NasdaqGS:LXRX) - **Event**: 44th Annual JPMorgan Healthcare Conference - **Date**: January 15, 2026 Key Points Industry and Company Background - Lexicon Pharmaceuticals was founded 30 years ago with a focus on gene research, creating knockout mouse lines for 5,000 genes, identifying 200 genes of interest [2][3] - The company has conducted over 80 clinical trials, resulting in the approval of two medicines in the U.S., including INPEFA for heart failure and a novel approach for neuropathic pain [3][4] Product Pipeline and Therapeutic Areas - **Cardiometabolic Disease**: - INPEFA has been commercialized in the U.S. and is in phase three trials for hypertrophic cardiomyopathy (HCM) [5][9] - Zynquista is under regulatory discussions for type 1 diabetes [5][9] - LX9851 is a first-in-class non-incretin mechanism for obesity, currently licensed to Novo Nordisk [5][19] - **Pain Management**: - Pivapladin is a first-in-class AAK1 inhibitor for neuropathic pain, entering phase three trials in 2026 [6][18] - There is a significant unmet need in neuropathic pain, with approximately 9 million patients in the U.S. suffering from diabetic peripheral neuropathic pain (DPNP) [16][31] Clinical Trials and Regulatory Pathways - The SONATA trial for HCM is progressing well, with enrollment expected to conclude in the first half of 2026 [10][20] - The FDA has agreed on the parameters for resubmission of Zynquista, focusing on prospective data to assess the risk of diabetic ketoacidosis [27][28] - Pivapladin has shown significant placebo-adjusted improvements in pain scores, supporting its advancement into phase three trials [18][32] Market Opportunities - The cardiometabolic market is of high interest, particularly for HCM, which affects about 1 million people in the U.S. [11][25] - The DPNP market is characterized by a lack of effective treatments, creating a strong demand for new non-opioid options like Pivapladin [16][32] - The obesity treatment market is shifting towards oral medications, with a focus on improving tolerability and long-term adherence [33] Financial Position and Future Goals - Lexicon ended the previous year with approximately $125 million in cash, supporting operations into 2027 [20] - Goals for 2026 include advancing the late-stage pipeline, supporting partnerships with Novo Nordisk and Viatris, and maintaining financial discipline [20][36] Additional Insights - The company is focused on operational excellence and has implemented a virtual sales force for INPEFA to ensure continuous availability [8] - Legislative support for non-opioid pain treatments is growing, which may facilitate market access for Pivapladin [17][32] Conclusion Lexicon Pharmaceuticals is strategically positioned in the cardiometabolic and pain management sectors, with a robust pipeline and significant market opportunities. The company is focused on advancing its clinical trials and regulatory submissions while maintaining a strong financial position to support long-term growth.

Core Insights - Lexicon Pharmaceuticals has made significant progress in its R&D initiatives and operational strategies, positioning itself for a pivotal year in 2026 [3][4]. R&D and Pipeline Highlights - Pilavapadin (LX9211) is being developed for Diabetic Peripheral Neuropathic Pain (DPNP) and has shown a two-point reduction in average daily pain scores in a Phase 2b study [7]. - All IND-enabling studies for LX9851, a drug for obesity, have been completed and submitted to Novo Nordisk, with potential milestone payments of up to $1 billion [5][7]. - The SONATA-HCM Phase 3 study of sotagliflozin is on track for enrollment completion by 2026, with 130 sites initiated across 20 countries [14]. Financial Performance - Total revenues for Q3 2025 increased to $14.2 million from $1.8 million in Q3 2024, primarily driven by licensing revenue from Novo Nordisk [9]. - R&D expenses decreased to $18.8 million in Q3 2025 from $25.8 million in Q3 2024, reflecting lower external research costs [10]. - SG&A expenses significantly decreased to $7.6 million in Q3 2025 from $39.6 million in Q3 2024 due to strategic repositioning [11]. Net Loss and Cash Position - The net loss for Q3 2025 was $12.8 million, or $0.04 per share, a reduction from a net loss of $64.8 million, or $0.18 per share, in Q3 2024 [12]. - As of September 30, 2025, Lexicon had $145.0 million in cash and investments, down from $238.0 million at the end of 2024 [13].